Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of ... ( LAUSANNE Switzerland and WOBURN M...)

HOME >> MEDICINE >> TECHNOLOGY

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

Date:8/4/2009

LAUSANNE, Switzerland and WOBURN, Massachusetts, August 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a privately held biotech company based in Woburn, Massachusetts focusing on the development of novel therapeutics for type 2 diabetes, cancer, and cardiovascular disease, announce the signature of an exclusive license agreement for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose disposal following a glucose challenge, two key goals in the management of type 2 diabetes.

Under the terms of the agreement, Debiopharm shall pay Mercury for continued research and development support, predefined advanced milestone payments during the development of the compound and a royalty based on net sales of commercialised product. First entry into man is expected for 2012.

"We are very enthusiastic about our collaboration with an experienced innovative biotech company like Mercury. Diabetes is a major cause of morbidity and mortality by disease globally and we are determined to improve the quality of patient's lives by developing a new therapy," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group."

"This alliance with Debiopharm represents important validation of Mercury's technology and of the growing appreciation of AMPK as a novel drug target for metabolic diseases. The development of an orally available direct activator of AMPK has the potential to be a first-in-class therapeutic for type 2 diabetes, hyperlipidemia, and a number of indications in oncology," added Dr.
'/>"/>

SOURCE The Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
2. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
3. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
4. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
5. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
6. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
7. Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative
8. Top Medical Research Centers Form Velos Advisory Group for Service-Oriented Architecture
9. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
10. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
11. The Villa Group Informs on Mexico Travel Plans in Wake of Swine Flu Outbreak

Post Your Comments:

(Date:5/20/2013)... Quebec , May 20, 2013 Valeant Pharmaceuticals International, ... members of its senior management team will make a presentation ... on Tuesday, June 11, 2013 at 9:20 a.m. PT. The ... Los Angeles, CA. A live ... on the company,s Web site at www.valeant.com . Click ...

(Date:5/20/2013)... BATESVILLE, Ind. , May 20, 2013 Hill-Rom ... to listen to a management presentation at the 38 ... Boston on May 30, 2013, ... ) You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ...

(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...

Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2 Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3

[0] Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference [0] Hill-Rom to Participate in the 38th Annual Deutsche Bank Health Care Conference [0] Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt

... Ontario, July 18, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... available for on-demand viewing at the RetailInvestorConferences website. ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About CardioGenics ...

... July 18, 2011 Coronado Biosciences, Inc. (the "Company"), ... immunotherapy agents for the treatment of autoimmune diseases and ... on Form 10 with the Securities and Exchange Commission ... the purpose of becoming a reporting company. The filing ...

Cached Medicine Technology:CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2 Coronado Biosciences Files to Become a Public Reporting Company 2

CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com Coronado Biosciences Files to Become a Public Reporting Company

(Date:5/21/2013)... According to the Center for Disease Control and Prevention (CDC), ... Over 800,000 of these bites require medical attention, half of ... aware of the danger that dog bites pose to their ... may sustain more serious injuries than an adult. For ... of 5 and 9 are at the greatest risk of ...

(Date:5/20/2013)... USA Book News announced Monday that "The ... won the top honor in its 2013 International Book ... multitude of international titles published from 2011-2013, "The Infinity ... both mainstream and new age audiences looking to improve ... , “The Infinity Zone” is a phenomenon ...

(Date:5/20/2013)... This week has been dedicated as National Dog Bite Prevention ... an awareness campaign designated to help prevent dog bite injuries ... properly train their pets, and educate children on how to ... at Buckfire & Buckfire, P.C. represent victims of dog bites ... law firm is a large advocate of this week as ...

(Date:5/20/2013)... Minneapolis, MN (PRWEB) May 20, 2013 When ... right bed is only part of the process. Much of ... over the internet involves not knowing what to expect. ... expert advice consumers can use to ensure their purchase proves ... When You Buy a Mattress Online ”, readers find helpful ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 The new ... lives and health of all Americans. However, not all ... immediate impact as some might take up to 2014 ... Human Services (HHS), some states are currently moving forward ... Insurance Marketplaces, such as: Iowa, Michigan, New Hampshire, and ...

Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries 2 Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2 Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3 Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2 Health News:See What to Expect When You Buy a Mattress Online With Latest Guide From Best Mattress Online 2 Health News:Review of Health Bill Impact in 2014 2 Health News:Review of Health Bill Impact in 2014 3

[0] Personal Injury Law Firm Announces New Informational Graphic Regarding Dog Bite Injuries [0] Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards [0] Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week [0] See What to Expect When You Buy a Mattress Online With Latest Guide From Best Mattress Online [0] Review of Health Bill Impact in 2014

... ... launches SafeConsole 4.0, the web management software for SafeStick, the secure USB flash drive. ... administrators through a series of new features and range of licensing options. , ... Washington, DC (PRWEB) December ...

... , , ... a new market research report is available in ... Industry in the U.S. and its International Trade ... , The newly published In-Vitro Diagnostic Substance Manufacturing ...

... , , , ... a new market research report is available in ... Autoimmune Diseases Therapeutics - Market Forecasts to 2015, ... , http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , Summary ...

... , SANTA CLARA, Calif., Dec. 15 ... into Santa Clara County for the first time since ... Administrators will be assuming responsibilities and provider contracts previously ... , Operating on a locally based healthcare philosophy, Coastal ...

... is widely thought to be the major form of the ... Research Program (MHRP) researchers, however, have demonstrated that essentially all ... of red blood cells isolated from each of 30 normal ... PLoS ONE , and can be accessed here. ...

... 2009Do good-looking people really benefit from their looks, and in ... Georgia and the University of Kansas found that yes; attractive ... an increased sense of psychological well-being. This seems like common ... each year trying to become more attractive. However, the study, ...

BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition]Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Coastal Healthcare Administrators Expands Provider Network to Santa Clara County New insight into selective binding properties of infectious HIV The importance of attractiveness depends on where you live

FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...

... QuickCast® Cast-like splints Slip ... dryer, and QuickCast conforms to ... cools. Reheat to adjust and ... coated with a temperature-sensitive polymer ...

... strong, the ThumSaver CMC Short lessens symptoms of ... and/or MP joints of the thumb. The ThumSaver ... IP joint motion for function. Includes felt padding ... and for rest due to repetitive stress injuries. ...

... an excellent choice to treat DeQuervain's Tendonitis, ... basal joint arthritis, advanced carpal tunnel syndrome ... and wrist. Distal palmar crease contour ... full finger dexterity. Constructed from an ...

Medicine Products:

FREEDOM® Memory Thumb Spica QuickCast® Sport Thumb Splint ThumSaver™ CMC Short 2087 LIGHTWEIGHT BREATHABLE WRIST/THUMB SPLINT